OOIR: Observatory of International Research

Papers

(The H4-Index of British Journal of Clinical Pharmacology is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Recent developments of HDAC inhibitors: Emerging indications and novel molecules	215
Potentially inappropriate prescribing and its associations with health‐related and system‐related outcomes in hospitalised older adults: A systematic review and meta‐analysis	75
Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside—a systematic review and meta‐analysis	63
Machine learning in pharmacometrics: Opportunities and challenges	59
Pharmacovigilance‐based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections	56
Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: An open label, prospective cohort trial with matched controls	51
Fatal adverse drug reactions: A worldwide perspective in the World Health Organization pharmacovigilance database	46
Drug–drug interactions with warfarin: A systematic review and meta‐analysis	46
Warfarin dosing algorithms: A systematic review	45
Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO	45
Night‐time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole	45
Identification of different side effects between PARP inhibitors and their polypharmacological multi‐target rationale	45
Trends in polypharmacy and potentially inappropriate medication (PIM) in older and middle‐aged people treated for diabetes	41
Effect of lipophilicity on drug distribution and elimination: Influence of obesity	39
Learning from remote decentralised clinical trial experiences: A qualitative analysis of interviews with trial personnel, patient representatives and other stakeholders	39
Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple‐dose study	38
Dissecting the IL‐6 pathway in cardiometabolic disease: A Mendelian randomization study on both IL6 and IL6R	38
Changes in antibiotic prescribing following COVID‐19 restrictions: Lessons for post‐pandemic antibiotic stewardship	38
The environmental impact of inhalers for asthma: A green challenge and a golden opportunity	37
Zinc supplementation as an adjunct therapy for COVID‐19: Challenges and opportunities	37
Pharmacovigilance in low‐ and middle‐income countries: A review with particular focus on Africa	37
Dose prediction for repurposing nitazoxanide in SARS‐CoV‐2 treatment or chemoprophylaxis	37
Review of pharmacological options for the treatment of Chagas disease	36
A systematic review of methods used to conduct decentralised clinical trials	36
The median effective concentration of propofol with different doses of esketamine during gastrointestinal endoscopy in elderly patients: A randomized controlled trial	36

A placebo‐controlled investigation of the analgesic effects, abuse liability, safety and tolerability of a range of oral cannabidiol doses in healthy humans	35
Pharmacological profile and effects of mitotane in adrenocortical carcinoma	34
Antiplatelet therapy in cardiovascular disease: Current status and future directions	34
Statin liver safety in non‐alcoholic fatty liver disease: A systematic review and metanalysis	33
A randomized single and multiple ascending dose study in healthy volunteers of LTI‐291, a centrally penetrant glucocerebrosidase activator	32
Ethical issues in therapeutic use and research in pregnant and breastfeeding women	31